|Mr. Christopher P. Spooner||Chief Exec. Officer and Exec. Director||1.09M||N/A||N/A|
|Mr. Alan Musgrave Olby ACA, B.A.||Chief Financial Officer and Director||203k||N/A||46|
|Ms. Jayne Burrell||Group Gen. Counsel and Company Sec.||N/A||N/A||42|
|Mr. Nairn McMaster||Head of Intercontinental||N/A||N/A||N/A|
|Mr. Louis Derek Payet||Head of Europe & APAC||N/A||N/A||N/A|
Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. It provides Silhouette Soft, a resorbable poly-L-lactic acid(PLLA)/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. The company also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth. It serves healthcare providers and plastic surgeons. The company was formerly known as Sinclair IS Pharma plc and changed its name to Sinclair Pharma plc in December 2015. Sinclair Pharma plc was founded in 1971 and is headquartered in London, the United Kingdom.
Sinclair Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.